Skip to content
Politically.com Search all
Menu

New Hampshire 2026

SB 465

classifying xylazine as a schedule III controlled drug.

Open original source Back to bills
Source: Open States / PluralUpdated 2026-09-12 08:11:03 UTC.

Source-supplied history

Actions

  1. Inexpedient to Legislate: MA VV 04/23/2026 HJ 11 P. 55

    failure

  2. Minority Committee Report: Ought to Pass

    committee-passage-favorable

  3. Majority Committee Report: Inexpedient to Legislate 04/14/2026 (Vote 11-5; RC)

    committee-failure

  4. Executive Session: 04/14/2026 01:00 pm GP 153

  5. Full Committee Work Session: 04/07/2026 01:00 pm GP 153

  6. Public Hearing: 03/31/2026 01:30 pm GP 153

  7. Introduced (in recess of) 03/12/2026 and referred to Environment and Agriculture HJ 8 P. 114

    introduction, referral-committee

  8. Ought to Pass with Amendment #2026-0842s, MA, VV; OT3rdg; 03/05/2026; SJ 5

    committee-passage-favorable, passage

  9. Committee Amendment # 2026-0842s, AA, VV; 03/05/2026; SJ 5

  10. Committee Report: Ought to Pass with Amendment # 2026-0842s, 03/05/2026; Vote 5-0; CC; SC 8

    committee-passage-favorable

  11. Hearing: 02/10/2026, Room 100, SH, 01:30 pm; SC 5A

  12. Introduced 01/07/2026 and Referred to Judiciary; SJ 1

    introduction, referral-committee

Recorded votes

Roll calls

No recorded vote is supplied for this bill.

When supplied by the API

Related measures

No resolvable related measure is supplied.